We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.18 | -1.27% | 91.90 | 91.45 | 92.00 | 94.03 | 91.33 | 93.99 | 1,753,124 | 16:40:00 |
From May 2019 to May 2024
By Colin Kellaher
Regeneron Pharmaceuticals Inc. and Sanofi SA on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of Dupixent to treat children with severe atopic dermatitis.
The companies said the recommendation covers the treatment of patients ages six to 11 years with severe atopic dermatitis who are candidates for systemic therapy.
The European Commission, which generally follows the CHMP's advice, is expected to announce a final decision in the coming months, the companies said.
Dupixent is already approved for the treatment of uncontrolled moderate-to-severe atopic dermatitis for people 12 years of age and older in the EU and six years of age and older in the U.S.
Regeneron, of Tarrytown, N.Y., created Dupixent and markets it jointly in the U.S. with France's Sanofi under a 2007 collaboration agreement. Sanofi markets the product internationally.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 16, 2020 08:36 ET (12:36 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
